|
CONTACT: Jeffrey B. Davis SmallCaps Online LLC (212) 554-4158 (phone) (212) 554-4058 (fax) info@SmallCapsOnline.com
Please Visit SmallCaps' Web Site at www.SmallCapsOnline.com for Detailed Report New York, NY, April 22, 1999 - SmallCaps Online LLC announced today that it has initiated coverage of Cell Therapeutics Inc. (Nasdaq: CTIC) with a BUY recommendation. The full text of this report can be accessed at SmallCaps' web site, at www.SmallCapsOnline.com. Jeffrey B. Davis, President of SmallCaps stated, "We are very impressed with Cell Therapeutics from many different perspectives. The company has not only diversified its product risk across a broad pipeline of very promising oncology drug candidates, but it has also strengthened its management team and balance sheet. Over the next six to twelve months, we are expecting a steady stream of positive news events to come from CTIC, and feel that the stock is extremely undervalued, currently trading roughly at cash value." Excerpts from the report follow: CTIC is an emerging pharmaceutical company focusing on the discovery, development, and commercialization of drugs useful in treating cancer and the serious side effects of various cancer treatments. The Company is building a deep, vertically integrated pipeline of cancer products targeting major unmet treatment needs, each with independent technology. This strategy enables use of multiple CTIC products by the same clinician and patient, and protects against the failure or ineffectiveness of any one particular technology. CTIC's lead product, Lisofylline ("LSF"), is in trials for two different indications: treating the side effects of high-dose chemotherapy and radiation, and for treatment of patients with acute respiratory distress syndrome (ARDS) and acute lung injury (ALI). CTIC has partnered with Johnson & Johnson ("JNJ") for the development of Lisofylline; CTIC is actively seeking additional corporate partners for other drug candidates. We are initiating coverage of CTIC with a BUY rating, and recommend purchase of CTIC by investors tolerant of the risks associated with small-cap equity investments. Integrated Oncology Strategy --Broad, Late-Stage Product Pipeline
Strong Financial Position, Low Burn and Partnering Opportunities -- Trading at Cash Value
Milestones - Strong Flow of Near-Term Corporate Events
SmallCaps Online LLC is a registered investment advisor focused on identifying emerging growth companies in the healthcare and information technology sectors that offer compelling investment opportunities over the long term. By providing comprehensive financial services, including corporate finance, M&A advisory, strategic partnering and communications consulting, the company positions itself to provide a fully integrated package of value-added services to emerging growth companies.
The information in this press release has been obtained from sources that SmallCaps Online LLC believes to be reliable, but the Company does not guarantee its accuracy or completeness. Neither the information nor any opinion expressed constitutes a solicitation by SmallCaps Online LLC for the purchase or sale of any securities. SmallCaps Online LLC has performed investment banking, consulting or other services for CTIC and may solicit investment banking, consulting or other business from, any company mentioned in this release. SmallCaps Online LLC or persons associated with SmallCaps Online LLC may at anytime be long or short any of the securities referred to herein and may make purchases or sales thereof while the Company's reports are in circulation or posted on the SmallCaps Online LLC web site at www.SmallCapsOnline.com. This material, or any portion thereof, may not be reproduced without prior permission from SmallCaps Online LLC. SmallCaps Online LLC is not responsible for the contents of this document that is intended for electronic transmission and could be thus subjected to tampering or alteration. Copyright © 1999 by SmallCaps Online LLC. All rights reserved. |